


**Newly Reported Drugs:** The following drugs were reported to NFLIS-Drug for the first time between **January 1, 2021, and March 31, 2021.**




**South**

**MDMB-4en-PICA**




**Midwest**

**para-Chlorofentanyl**




**Northeast**


**ADB-BINACA**




**4F-ABUTINACA**



**5F-EDMB-PICA**



**AP-238**




**Snapshot of Drug Reports Received by NFLIS-Drug**

The tables on the right present the top five drug reports in each category received by NFLIS-Drug between January 1, 2021, and March 31, 2021.

Cannabinoids	34,492	Synthetic Cannabinoids	2,911	Phenethylamines	86,891
Cannabis/THC	33,087	MDMB-4en-PINACA	1,297	Methamphetamine	82,984
Cannabidiol	813	Fluoro-MDMB-PICA <sup>1</sup>	438	Amphetamine	1,590
Cannabinol	211	Fluoro-MDMB-BUTINACA <sup>1</sup>	182	MDMA	1,079
Tetrahydrocannabinolic acid A	204	ADB-BUTINACA	112	MDA	167
delta-8-Tetrahydrocannabinol	98	Fluoro-MDMB-BUTICA <sup>1</sup>	101	Lisdexamfetamine	131
Selected Benzodiazepines	7,956	Selected Synthetic Cathinones	2,809	Selected Narcotic Analgesics	42,384
Etizolam	1,161	Eutylone	2,381	Phenyl fentanyl	151
Flualprazolam	743	BMDP	81	Fluorofentanyl <sup>1</sup>	77
Clonazolam	692	N-Ethylpentylone	54	Brorphine	28
Flubromazolam	142	3,4-Methylenedioxy PV8	45	Isotonitazene	26
Diclazepam	53	Fluoro-methyl-alpha-PVP <sup>1</sup>	17	Metonitazene	23

<sup>1</sup> Includes all positional and nonspecified isomers as reported by participating laboratories.

**Percentage of All NFLIS-Drug Items Containing Fentanyl and at Least One Other Drug<sup>2</sup>**



<sup>2</sup> The data presented in these figures do not necessarily reflect true combinations (e.g., powders mixed together) but also include instances of separate drugs reported together in the same item.

**Data Disclaimer:** Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in April 2021 and include drug reports received by NFLIS-Drug through March 2021. Data in the Newly Reported Drugs and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after January 1, 2020. Data in the Percentage of All NFLIS-Drug Items Containing Fentanyl and at Least One Other Drug section include all drugs submitted to NFLIS-Drug in 2018, 2019, and 2020, and retrieved from the NFLIS-Drug database on April 4, 2021. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/Reports.aspx>. Questions and comments: [DEANFLIS@rti.org](mailto:DEANFLIS@rti.org)

